Table 2.

Risk of arterial thromboembolic events (ATEs) up to 36 months of follow-up among colorectal cancer patients diagnosed during 2005–2007, no ATE history, and receiving chemotherapy with or without bevacizumab for newly diagnosed or recurrent disease

	Event no.a	Event rate (per 1000 person-years)	Hazard ratio (HR, 95% CI)b
BEV use	56	15.90	1.82 (1.20, 2.76)*
Non-BEV	109	12.38	1.0

^aThe cohort included a total of 6370 patients without history of ATE. The follow-up times were 3522 and 8807 person-years in the BEV-use and non-BEV use groups, respectively.

^bCox-proportional hazards (PHs) model adjusted for the effects of radiation, surgery, age at chemotherapy initiation, sex, hematologic comorbidity other than ATE and time-dependent use of irinotecan, oxaliplatin, and 5-FU.

*P < 0.001.